EGFR mutations as a predictive marker of cytotoxic chemotherapy

Abstract Background Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) are important predictive markers for the response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Whether EGFR mutations can also predict the clinical outcomes in NSCLC patients receiving chem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2012-08, Vol.77 (2), p.433-437
Hauptverfasser:	Park, Jin Hyun, Lee, Se-Hoon, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan, Yang, Seok-Chul, Kim, Young Whan, Heo, Dae Seog
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Cytotoxic chemotherapy EGFR mutation Exons Female Gemcitabine Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Medical sciences Middle Aged Mutation Pneumology Prognosis Pulmonary/Respiratory Receptor, Epidermal Growth Factor - genetics Survival Analysis Taxane Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!